Lumvoa receives FDA approval and launches immediately, with label differentiation supporting VRDN's competition with Tepezza

Overview

This report focuses on FDA approval of VRDN's Lumvoa and the start of commercialization, with emphasis on evaluating its label, efficacy, safety, pricing, and launch readiness. Goldman Sachs believes the approval came slightly ahead of the PDUFA date, and while the label was broadly in line with expectations, it provides a differentiated basis to compete with Tepezza in chronic TED data, dosing convenience, and certain efficacy metrics.

Core views

The core view is that Lumvoa may leverage its active and chronic TED label, fewer infusions, shorter treatment course, and numerically stronger performance on certain efficacy metrics to gain share from Tepezza and expand use among chronic TED patients; pricing is expected to remain at parity with Tepezza on a per-course basis to support payer coverage; key uncertainties lie in commercialization execution, TED market size, competing SC programs, and safety monitoring.

Analysis framework

The report uses event-driven label interpretation and peer-drug comparative analysis, comparing Lumvoa with Tepezza across eligible patient populations, efficacy endpoints, speed of onset, dosing regimen, safety warnings, reimbursement coverage, and pricing assumptions, and uses a DCF framework to assess VRDN's target price.

Methodology notes

• Valuation methodsDCF

  The 12-month target price is based on a DCF methodology

  Goldman Sachs' $35 target price is based on a DCF methodology and does not include M&A considerations; key assumptions include a 15% WACC and 0% terminal growth rate. The WACC references the 15%-19% risk range for pre-commercial companies, while the terminal growth rate is based on VRDN's TED patents and potential patent term extension expiring shortly after 2040.

• Factor analysisGS Factor Profile

  Uses growth, financial returns, valuation multiples, and composite factors to compare stock characteristics

  The report discloses the Goldman Sachs Factor Profile methodology, which compares growth, financial returns, valuation multiples, and composite metrics using standardized percentiles across covered stocks and industry peers; this section explains the research framework and is not the primary source of conclusions for the Lumvoa event.

• M&A scenarioM&A Rank

  Uses levels 1 to 3 to assess the probability of a company becoming an acquisition target

  Goldman Sachs discloses its M&A Rank framework, in which 1 represents high probability, 2 medium probability, and 3 low probability; the valuation section of this report explicitly states that the $35 target price does not incorporate M&A considerations.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• VRDN.US

  Covered company common stock, with value primarily driven by Lumvoa commercialization and advancement of the TED pipeline.

  Strengths

  Lumvoa has received FDA approval and launched immediately; its label covers active and chronic TED, its dosing frequency and treatment course are shorter than Tepezza, and some efficacy data are numerically more favorable.

  Weaknesses

  Lumvoa is still in the early stage of commercialization, pricing has not yet been disclosed, payer coverage and physician adoption remain to be validated, and the label also includes safety concerns such as IBD and hearing impairment.

  Comparison

  Relative to Tepezza, Lumvoa is differentiated in patient coverage, dosing convenience, and certain response metrics; Tepezza already has established coverage and market presence.

  Risks

  TED market potential below expectations, progress by competing SC programs, regulatory or commercialization outcomes below expectations, safety events, and payer restrictions could all affect VRDN.US performance.

Key data

• Report date2026-06-29The report was published around the trading session following Lumvoa's approval.
• Approval eventLumvoa received FDA approval and initiated commercial launchThe indication is thyroid eye disease (TED), and VRDN plans an immediate launch.
• Label coverageBoth active and chronic TED data are included in the labelThe report considers this an important differentiating point for Lumvoa versus Tepezza, because Section 14 of the Tepezza label mainly includes data from active-phase patients.
• Proptosis responsePlacebo-adjusted PRR was 65% in active-phase patientsThe report says this figure is above some levels within the average range across Tepezza's two studies.
• Diplopia responsePlacebo-adjusted diplopia response rate was approximately 39%The report compares this with approximately 28% for Tepezza and notes that Lumvoa disclosed both diplopia resolution rate and diplopia response rate.
• Dosing regimen5 IV infusions every 3 weeks, in less than 4 months, 30-45 minutes eachTepezza requires 8 IV infusions, about 6 months, and 60-90 minutes each.
• Safety concernsIBD, hyperglycemia, hearing impairment, infusion reactionsThe Lumvoa label includes an IBD warning, which the report believes may reflect the FDA viewing IBD as a class effect of IGF-1R inhibitors.
• Incidence of hearing impairment15% for Lumvoa versus 6% for placeboThe report compares this with 19% in two post-marketing trials in the Tepezza label.
• Pricing referenceTepezza WAC is approximately $19,450/vial, about $450K per treatment courseThe company has not yet disclosed Lumvoa's list price, but reiterated that parity with Tepezza on a per-course basis would help achieve parity in reimbursement coverage.
• Reimbursement coverage referenceTepezza currently covers approximately 85% of covered livesThe report believes payers are unlikely to adopt exclusive or preferred coverage solely based on Lumvoa's value proposition.
• Target price$3512-month target price, based on a DCF methodology.
• Disclosure page price$17.90Shown in the company-specific regulatory disclosure section.
• Key pipeline catalystsVRDN-003/elegrobart BLA planned for 1Q27; VRDN-008 Ph.1 IgG PoC data expected in 2H26; TSHR project IND expected in 4Q26VRDN-006 is expected to communicate its development plan in 2026.

Impact & implications

Lumvoa's approval moves VRDN further from clinical development into the commercialization validation stage. If it delivers on its label differentiation, reimbursement coverage, and treatment-course parity pricing in the real world, it could drive share shifts in the TED market and expand treatment penetration in chronic TED; if the subcutaneous formulation elegrobart is successfully launched later, it could further enhance convenience and competitiveness.

Risks

• Commercialization speed, patient access, and reimbursement coverage for Lumvoa and follow-on products such as elegrobart may fall short of expectations.
• The size of the TED market or treatment penetration in chronic TED may be lower than company and market assumptions.
• Tepezza, other SC programs, and innovative TED treatment approaches may create more intense competition.
• Safety issues including IBD, hyperglycemia, hearing impairment, infusion reactions, elevated CPK, and hypertension may affect physician and patient adoption.
• Lumvoa's list price has not yet been disclosed; if the treatment-course parity strategy with Tepezza fails to gain payer support, sales ramp may be affected.
• Pipeline assets including VRDN-003/elegrobart, VRDN-008, the TSHR program, and VRDN-006 face regulatory, clinical, and development timing uncertainty.

What to watch

• Early Lumvoa launch patient enrollment, prescription conversion, and the effectiveness of ViridianCares patient support.
• Lumvoa's final list price, execution of treatment-course parity with Tepezza, and the scope of payer coverage.
• Whether promotion to chronic TED patients generates incremental demand and market expansion.
• The incidence and regulatory feedback in real-world use for label warnings such as IBD, hearing impairment, and hyperglycemia.
• Progress of the BLA submission for VRDN-003/elegrobart, planned for 1Q27.
• Healthy volunteer Ph.1 IgG PoC data for VRDN-008 to be disclosed in 2H26.
• Progress of the IND submission for the TSHR program in 4Q26.
• The development plan for VRDN-006 to be disclosed in 2026.